COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå : Çڵ鸵, À¯Çü, ÃÖÁ¾ ¿ëµµ, ±¹°¡ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2023-2030³â)
Rapid POC Covid-19 Antigen Market with COVID-19 Impact Analysis, By Handling, By Type, By End-Use, By Country, and By Region - Industry Analysis, Market Size,Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1299771
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,510,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,453,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,841,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÁÖ¿ä ³»¿ë

COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå ±Ô¸ð´Â 2022³â 305¸¸ 6,000´Þ·¯·Î 2023³âºÎÅÍ 2030³â±îÁö CAGR 8.8%·Î È®´ë

COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - ½ÃÀå ¿ªÇÐ:

½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ¹æ´ëÇÑ ¿ä±¸ »çÇ×, Äڷγª ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ Á¤ºÎ °Ë»ç, ±ÔÁ¦ ±â°üÀÇ Á¦Ç° ½ÂÀÎ Áõ°¡´Â ½Å¼Ó POC COVID-19 Ç׿ø ½ÃÀåÀÇ ¼¼°è ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª Àü¿°º´ÀÇ Á¾½Ä°ú »ç·Ê ¼öÀÇ °¨¼Ò´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, COVID-19 Ç׿ø ½Å¼Ó POCÀÇ ¼ºÀåÀº Àü ¼¼°è °øÁß º¸°Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ ½ÅÁ¾ Äڷγª ¹ÙÀÌ·¯½º ±ÕÁÖÀÇ °ËÃâÀº COVID-19 Ç׿ø ½Å¼Ó POC ºÐ¾ßÀÇ °³¹ß ¹× ¿¬±¸ ³ë·ÂÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Àü¿°º´Àº COVID-19 Ç׿ø ½Å¼Ó POC ºÎ¹®À» Áõ°¡½ÃÄ×°í, ±â¾÷µéÀº Á¤È®ÇÏ°í ºü¸¥ ¹ÙÀÌ·¯½º °ËÃâ ±â¼úÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀåÀº Çڵ鸵, À¯Çü, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Çڵ鸵¿¡ µû¶ó RNA ÃßÃ⠽ýºÅÛÀ̶ó´Â ÇϳªÀÇ ¹üÁÖ·Î ³ª´µ¸ç, RNA ÃßÃ⠽ýºÅÛÀº Á¤ºÎ ±â°ü, °øÁß º¸°Ç ¿¬±¸¼Ò, È£ÅÚ, »ó¾÷ ¿¬±¸¼Ò µî¿¡¼­ äÅõǾî ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº À¯Çüº°·Î »óÀεÎ(np) ¸éºÀ, ±¸ÀεÎ(op) ¸éºÀ, ºñ°­ ¸éºÀ, Ÿ¾× µî 4°¡Áö ¹üÁÖ·Î ³ª´µ¸ç, COVID-19 °ËÃâÀ» À§ÇÑ °Ë»ç ¸éºÀ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÀεÎ(np) ¸éºÀÀº ÀϺΠºÐÀÚ Áø´Ü °Ë»ç¿¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÌ ºÐ¾ßÀÇ ¼ö¿ä´Â ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó È£½ºÇÇÅ»¸®Æ¼, ÀçÅà ÀÇ·á, Áø´Ü ¼¾ÅÍ ¹× Ŭ¸®´Ð, ±âŸ µî 4°³ ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. È£½ºÇÇÅ»¸®Æ¼ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. COVID-19 È®»ê ¹æÁö¸¦ À§ÇØ COVID-19 °Ë»ç¸¦ ½ÃÇàÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, À̴ ȣ½ºÇÇÅ»¸®Æ¼Å¸ ºÎ¹®ÀÇ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - °æÀï »óȲ:

COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀåÀÇ ½ÃÀå ±â¾÷µéÀº ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ È®´ëÇϱâ À§ÇØ Àü·«Àû Á¦ÈÞ, R&D ºñ¿ë, M&A, Áö¸®Àû È®Àå µîÀÇ Àü·«À» ½ÇÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, POC SARS-CoV-2 Áø´Ü Å×½ºÆ®ÀÇ ½ÃÀå °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ ´Ù¾çÇÑ °ø°ø ¹× ¹Î°£ ±â°üÀÇ ÅõÀÚ ¹× ÀÚ±Ý Á¶´ÞÀÌ Áõ°¡ÇÔ¿¡ µû¶ó COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀåÀÇ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¹é½Å Á¢Á¾ ÀÌÈÄ¿¡µµ COVID-19 ȯÀÚÀÇ Áõ°¡´Â ½ÃÀå ¼öÀÍÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 4¿ù IIT Ä«¶ó±×Ç®Àº COVID-19 Áø´ÜÀ» À§ÇÑ ÇÙ»ê ±â¹Ý POC Áø´Ü ±â±âÀÎ COVIDIRAPÀ» ¹ßÇ¥Çߴµ¥, COVIDIRAPÀÇ ÁøÈ­ ¹öÀüÀº SARS-CoV-2¿Í °°Àº º´¿ø¼º °¨¿°ÁõÀÇ ½Å¼ÓÇÑ Áø´ÜÀ» À§ÇØ ´Ü°èÀû µî¿Â ÇÙ»ê °Ë»ç ±â¼úÀ» »ç¿ëÇÏ¿© ¿¬±¸ÆÀ¿¡ ÀÇÇØ °³¹ßµÇ¾ú½À´Ï´Ù.

¿¬±¸ÀÇ ÁÖ¿ä Æ¯Â¡

ÀÌ º¸°í¼­´Â COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀåÀÇ ½ÃÀå ±Ô¸ð, ¿¬Æò±Õ ¼ºÀå·ü(CAGR %), 2022³âÀ» ±âÁØ ¿¬µµ·Î ÇÑ ÃßÁ¤ ¹× ¿¹Ãø(2023-2030³â)À» Á¦°øÇÕ´Ï´Ù.

Á¶»ç º¸°í¼­´Â ´Ù¾çÇÑ ºÎ¹®/±¹°¡¿¡ °ÉÄ£ ÀáÀçÀû ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

ÀÌ Àüü º¸°í¼­´Â »õ·Î¿î ÅõÀÚ ±âȸ, ±âÁ¸ ±â¾÷ÀÌ Á÷¸éÇÑ °úÁ¦, ±×¸®°í ±Þ¼ÓÇÑ POC COVID-19 Ç׿ø ½ÃÀå¿¡¼­ Áö¼Ó°¡´ÉÇÑ ¼ºÀå ¿äÀÎÀ» ÆÄ¾ÇÇÕ´Ï´Ù.

½Å¼Ó POC COVID-19 Ç׿ø ½ÃÀå ±Ô¸ð, ¿¹Ãø, CAGR, ½ÃÀå ¿ªÇп¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº ¿¬±¸ ¹üÀ§¿¡¼­ ÀÚ¼¼È÷ ³íÀǵǸç, COVID-19 ÀÌÈÄ COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®µµ ´Ù·ì´Ï´Ù.

ÀÌ º¸°í¼­´Â »ç¿ëÀÚ¿¡°Ô COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °üÁ¡À» Á¦°øÇϱâ À§ÇØ COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀåÀÇ °æÀï »óȲ°ú ÁÖ¿ä Çõ½Å°¡ ºÐ¼®µµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ½ÃÀå ±Ô¸ð, ¼ºÀå·ü, ¸Å·Âµµ¸¦ ±âÁØÀ¸·Î ¸ðµç »ê¾÷ ºÎ¹®À» º¥Ä¡¸¶Å·ÇÏ´Â ¼ºÀå Àü¸Á ¸ÅÇÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä ½ÃÀå Âü¿©ÀÚ¸¦ ´Ù·ç´Â »ó¼¼ÇÑ ±â¾÷ °³¿ä¸¦ Á¦°øÇÏ¿© COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ±â¾÷ÀÇ À繫 Á¤º¸ ¹× Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

¶ÇÇÑ, ÀÌ º¸°í¼­´Â ¼¼°è ¹× Áö¿ªÀû Â÷¿ø¿¡¼­ ½ÃÀå¿¡ Âü¿©ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÇ ÁÖ¿ä ÀμöÇÕº´, Á¦ÈÞ ¹× ÇÕÀÛÅõÀÚ, ½ÅÁ¦Ç° Ãâ½Ã, R&D ¹× Áö¿ª È®Àå¿¡ ´ëÇØ¼­µµ ¾Ë¾Æº¾´Ï´Ù.

¼¼°è COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå º¸°í¼­´Â ÁÖ·Î °ø±Þ¾÷ü, ÅõÀÚÀÚ, ½Å±Ô ÁøÀÔÀÚ, À¯Åë¾÷ü, ±ÝÀ¶ ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå COVID-19 Ç׿ø ½Å¼Ó POC ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå COVID-19 Ç׿ø ½Å¼Ó POC »ê¾÷ Á¶»ç

Á¦5Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå »óȲ

Á¦7Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - Çڵ鸵º°

Á¦8Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - À¯Çüº°

Á¦9Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - ÃÖÁ¾ ¿ëµµº°

Á¦10Àå COVID-19 Ç׿ø ½Å¼Ó POC ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - COVID-19 Ç׿ø ½Å¼Ó POC »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Rapid POC COVID-19 antigen market size was valued at USD 3.056.1 Million in 2022, expanding at a CAGR of 8.8% from 2023 to 2030.

Rapid POC COVID-19 Antigen is based on various formats and technology for detecting infected individuals and stopping further person-to-person transmission. Additionally, it offers faster results and is cost-effective as compared to other antibody tests. Moreover, rapid POC COVID-19 antigen is easy to use because it required no or little specialist training and it can be deployed in a high-risk environment such as educational institutions & homes.

Rapid POC COVID-19 Antigen Market- Market Dynamics:

Immense requirements for rapid diagnostics, government testing for coronavirus, and a rise in product approval by regulatory bodies are major factors expected to drive the demand for a rapid POC COVID-19 Antigen market globally. However, the end of the pandemic and a decrease in the number of cases may restrain the market growth over the forecast period.

Moreover, the growth of rapid POC COVID-19 antigen increased owing to its increased public health awareness globally. Furthermore, the detection of new coronavirus strains has increased development and research efforts in the rapid POC COVID-19 antigen sector. The pandemic has increased the rapid POC COVID-19 antigen sector, and companies Endeavour to develop accurate and quick viral detection technologies.

Rapid POC COVID-19 Antigen Market- Segmentation Analysis:

The Global Rapid POC COVID-19 Antigen Market is segmented on the basis of Handling, Type, End-Use, and Region.

The market is divided into one category based on Handling: RNA extraction systems. The adoption of RNA extraction systems across government bodies, public health laboratories, hospitals, and commercial laboratories has resulted in the growth for this segment.

The market is divided into four categories based on type: nasopharyngeal (np) swab, oropharyngeal (op) swab, nasal swabs, and saliva. Rising demand for testing swabs to detect COVID-19. Additionally, nasopharyngeal (np) swab required by several molecular diagnostic test that further expected to increase the segment demand.

The market is divided into four categories based on end-use: hospitals, home care, diagnostic centers & clinics, and others. The hospital sector is expected to possess the market share. Increasing cases of COVID-19 test being conducted to inhibit the spread of infection this can be attributed to increase the demand for hospital sector.

Rapid POC COVID-19 Antigen Market-Competitive Landscape:

Market players in the market for rapid POC COVID-19 antigen are implementing several strategies such as strategic collaborations, R&D spending, mergers & acquisitions, and geographical expansion to expand their market presence. Moreover, rising investment and funding by various public and private organizations to boost the development of POC SARS-CoV-2 diagnostic tests is expected to increase the demand for the rapid POC COVID-19 antigen market. Additionally, an increase in the number of COVID-19 patients even after vaccination is projected to propel market revenue. For instance, in April 2021, IIT Kharagpur announced COVIRAP, Its Nucleic acid-based POC Diagnostic Device for COVID-19 Diagnosis. The more advanced version of COVIRAP has been developed by the research team using a step-wise isothermal nucleic acid testing technology for the rapid diagnostics of pathogenic infections such as SARS-CoV-2 in individuals.

Key features of the study:

This proposed research study on rapid POC COVID-19 antigen market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year.

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for rapid POC COVID-19 antigen market.

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Rapid POC COVID-19 Antigen market

Impact of COVID-19 on rapid POC COVID-19 antigen market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on rapid POC COVID-19 antigen market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the rapid POC COVID-19 antigen market, we have also included competitive landscape and key innovator analysis for the rapid POC COVID-19 antigen market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

The report offersdetailed company profiling featuring major market participantswhich will help users to understand their financial information and strategic initiatives of players operating in the rapid POC COVID-19 antigen market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

The global rapid POC COVID-19 antigen market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RAPID POC COVID-19 ANTIGEN MARKET KEY PLAYERS

GLOBAL RAPID POC COVID-19 ANTIGEN MARKET, BY HANDLING

GLOBAL RAPID POC COVID-19 ANTIGEN MARKET, BY TYPE

GLOBAL RAPID POC COVID-19 ANTIGEN MARKET, BY END-USE

GLOBAL RAPID POC COVID-19 ANTIGEN MARKET, BY REGION

Table of Contents

1. Rapid POC Covid-19 Antigen Market Overview

2. Executive Summary

3. Rapid POC Covid-19 Antigen Key Market Trends

4. Rapid POC Covid-19 Antigen Industry Study

5. Rapid POC Covid-19 Antigen Market: COVID-19 Impact Analysis

6. Rapid POC Covid-19 Antigen Market Landscape

7. Rapid POC Covid-19 Antigen Market - By Handling

8. Rapid POC Covid-19 Antigen Market - By Type

9. Rapid POC Covid-19 Antigen Market - By End-Use

10. Rapid POC Covid-19 Antigen Market- By Geography

11. Key Vendor Analysis- Rapid POC Covid-19 Antigen Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â